Patients with sickle cell disease treated with high-dose crizanlizumab experienced lower annualized rates of sickle cell crisis compared to placebo treatment, regardless of their baseline use of hydroxyurea. Those treated with high-dose crizanlizumab remained without a sickle cell crisis on average significantly longer into the study period than those treated with placebo.

Read More